Results 191 to 200 of about 9,276,761 (294)

Estrogen synthesized in the central nervous system enhances MC4R expression and reduces food intake

open access: yesThe FEBS Journal, EarlyView.
Estrogen is regulated by the rate‐limiting enzyme aromatase. This study examines how neuroestrogens, estrogen produced in the brain, regulate appetite through the hypothalamus. Using ovariectomized, aromatase knockout, and brain‐specific aromatase‐restored mice, the study found that neuroestrogens suppress appetite by influencing genes like Mc4r.
Takanori Hayashi   +8 more
wiley   +1 more source

A post hoc analysis of migraine‐associated symptoms from the phase 3 randomized, double‐blind, sham‐controlled Trial of External trigeminal nerve stimulation for the Acute treatment of Migraine (TEAM) study

open access: yesHeadache: The Journal of Head and Face Pain, Volume 65, Issue 5, Page 779-790, May 2025.
Abstract Background The Trial of External trigeminal nerve stimulation (eTNS) for the Acute treatment of Migraine (TEAM) study demonstrated that eTNS use during active migraine resulted in significantly higher rates of resolution of migraine‐associated most bothersome symptom (MBS) compared to sham.
Gregory A. Panza   +2 more
wiley   +1 more source

Targeting Neuropeptide Receptors for Cancer Imaging and Therapy: Perspectives with Bombesin, Neurotensin, and Neuropeptide-Y Receptors

open access: yesJournal of Nuclear Medicine, 2014
C. Morgat   +5 more
semanticscholar   +1 more source

Low serum 25‐hydroxyvitamin D levels in migraine are not related to headache frequency: A case‐control study in patients with high‐frequency/chronic migraine

open access: yesHeadache: The Journal of Head and Face Pain, Volume 65, Issue 5, Page 863-870, May 2025.
Abstract Background Serum 25‐hydroxyvitamin D (25[OH]D) concentrations have been shown to be low in patients with migraine, but results are controversial regarding the current role of vitamin D in migraine severity. Using a case–control design, we aimed to evaluate serum 25(OH)D levels in a group of females with high‐frequency episodic migraine/chronic
Marina Haro   +6 more
wiley   +1 more source

Development and pharmacological characterization of novel multi‐ calcitonin gene‐related peptide and pituitary adenylate cyclase‐activating peptide receptor antagonists

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to provide proof‐of‐concept that multi‐receptor antagonist peptides can be generated by covalently linking independent antagonist peptides that block calcitonin gene‐related peptide (CGRP8‐37) or pituitary adenylate cyclase‐activating peptide (PACAP)/vasoactive intestinal peptide (VIP) (PACAP6‐38) activity ...
Zoe Tasma   +5 more
wiley   +1 more source

Postmarketing safety of migraine prophylactic monoclonal antibodies: An EudraVigilance database analysis of eptinezumab, fremanezumab, galcanezumab, and erenumab

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objectives/Background This study was undertaken to evaluate the postmarketing safety of monoclonal antibodies (mAbs) targeting the calcitonin gene‐related peptide pathway used for migraine prophylaxis through pharmacovigilance data analysis by examining suspected adverse events reported in Europe.
Victoria Nikitina   +3 more
wiley   +1 more source

Targeting the neuropeptide Y system in stress-related psychiatric disorders

open access: yesNeurobiology of Stress, 2014
N. Enman   +3 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy